|
|
Latest Non-Hodgkin's Lymphoma News
Istodax Active against Refractory Cutaneous T-cell Lymphoma (8/31/2010)
Final results from a Phase II clinical trial provide additional evidence that Istodax® (romidepsin) is active against refractory cutaneous T-cell lymphoma. These results were published in the Journal of Clinical Oncology.
Hepatitis B Virus Linked with Non-Hodgkin’s Lymphoma (8/17/2010)
Individuals with chronic hepatitis B virus (HBV) infection may have an increased risk of developing non-Hodgkin’s lymphoma (NHL), according to findings recently published in The Lancet Oncology.
High Circulating Vitamin D Levels Don’t Reduce Risk of Less Common Cancers (7/12/2010)
High levels of vitamin D in the bloodstream do not appear to reduce the risk of seven less common cancers: endometrial, esophageal, stomach, ovarian, pancreatic, kidney, and non-Hodgkin’s lymphoma.
Maintenance Therapy with Rituxan Prolongs Lymphoma Remission (5/26/2010)
Among patients with follicular lymphoma who responded to initial treatment with chemotherapy and Rituxan® (rituximab), those who received an additional two years of Rituxan as maintenance therapy remained free of lymphoma progression for longer than patients who did not receive maintenance therapy. The results of this Phase III clinical trial will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Survivors of Some Childhood Cancers May Face Cognitive Impairment (5/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.
Non-Hodgkin's Lymphoma News By Topic
Non-Hodgkin's Lymphoma - Screening/PreventionHepatitis B Virus Linked with Non-Hodgkin’s Lymphoma (8/17/2010)
Individuals with chronic hepatitis B virus (HBV) infection may have an increased risk of developing non-Hodgkin’s lymphoma (NHL), according to findings recently published in The Lancet Oncology.
High Circulating Vitamin D Levels Don’t Reduce Risk of Less Common Cancers (7/12/2010)
High levels of vitamin D in the bloodstream do not appear to reduce the risk of seven less common cancers: endometrial, esophageal, stomach, ovarian, pancreatic, kidney, and non-Hodgkin’s lymphoma.
September Is National Leukemia and Lymphoma Awareness Month (8/28/2009)
As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Cyclophosphamide May Increase Cancer Risk Among Patients with Rheumatoid Arthritis (3/10/2008)
A large study conducted in Canada reveals that patients who are treated for rheumatoid arthritis (RA) with the drug cyclophosphamide may have an increased risk for developing hematological cancers such as lymphoma.
Being Overweight Associated with Increased Risk of Several Cancers (2/19/2008)
Excess bodyweight increases the risk of developing several types of cancer, according to results recently published in The Lancet.
Non-Hodgkin's Lymphoma - Indolent/Low GradeMaintenance Therapy with Rituxan Prolongs Lymphoma Remission (5/26/2010)
Among patients with follicular lymphoma who responded to initial treatment with chemotherapy and Rituxan® (rituximab), those who received an additional two years of Rituxan as maintenance therapy remained free of lymphoma progression for longer than patients who did not receive maintenance therapy. The results of this Phase III clinical trial will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Children and Teens Have Better NHL Survival than Young Adults (3/15/2010)
Even after accounting for stage at diagnosis and subtype of non-Hodgkin’s lymphoma (NHL), children and teens with NHL have better survival than young adults with NHL. These results were published in the Archives of Pediatrics and Adolescent Medicine.
Idiotype Vaccine Improves Disease-free Survival in Patients with Follicular Lymphoma (6/8/2009)
BiovaxID, an individualized tumor-specific protein vaccine, prolongs disease-free survival in patients with advanced follicular lymphoma who experience complete remission for six months or longer following first-line treatment with the chemotherapy regimen PACE, according to the results of a study presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida.
Additional Evidence That Antibiotics Are Effective Against Gastric MALT Lymphomas (5/29/2009)
According to the results of a study published in the Annals of Oncology, antibiotic treatment of Helicobacter pylori infection results in a high rate of long-term survival among patients with localized, gastric MALT lymphoma.
Maintenance Rituxan® Prolongs Survival in Advanced Indolent Lymphoma (3/24/2009)
Maintenance Rituxan® (rituximab) given after standard chemotherapy significantly prolongs progression-free survival (PFS) in patients with advanced-stage indolent non-Hodgkin’s lymphoma, according to the results of a study published in the Journal of Clinical Oncology.
Non-Hodgkin's Lymphoma - Aggressive/Intermediate GradeSurvivors of Some Childhood Cancers May Face Cognitive Impairment (5/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.
Children and Teens Have Better NHL Survival than Young Adults (3/15/2010)
Even after accounting for stage at diagnosis and subtype of non-Hodgkin’s lymphoma (NHL), children and teens with NHL have better survival than young adults with NHL. These results were published in the Archives of Pediatrics and Adolescent Medicine.
Advances in the Treatment of Aggressive Non-Hodgkin’s Lymphoma (2/6/2009)
A Report from the 2008 Meeting of the American Society of Hematology
The American Society of Clinical Oncology 2008: Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia (2/2/2009)
At the 2008 meeting of the American Society of Clinical Oncology (ASCO), there were more than 100 abstracts devoted to the treatment of lymphoma. There is increasing evidence that survival of patients with lymphoma and chronic lymphocytic leukemia (CLL) is steadily increasing. New drugs are being developed at a reasonable rate, which creates the question of how best to incorporate all the available drugs in an optimal manner. Additionally, there appears to be significant progress in reduced-intensity allogeneic stem cell transplants for low-grade lymphomas.
New and Novel Agents for the Treatment of Non-Hodgkin’s Lymphoma: A Report from the 2008 Meeting of the American Society of Hematology (1/26/2009)
The 2008 ASH meeting featured several reports of new agents that are showing promise in the treatment of Non-Hodgkin’s Lymphoma.
Non-Hodgkin's Lymphoma - Highly Aggressive/High GradeSurvivors of Some Childhood Cancers May Face Cognitive Impairment (5/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.
Children and Teens Have Better NHL Survival than Young Adults (3/15/2010)
Even after accounting for stage at diagnosis and subtype of non-Hodgkin’s lymphoma (NHL), children and teens with NHL have better survival than young adults with NHL. These results were published in the Archives of Pediatrics and Adolescent Medicine.
The American Society of Clinical Oncology 2008: Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia (2/2/2009)
At the 2008 meeting of the American Society of Clinical Oncology (ASCO), there were more than 100 abstracts devoted to the treatment of lymphoma. There is increasing evidence that survival of patients with lymphoma and chronic lymphocytic leukemia (CLL) is steadily increasing. New drugs are being developed at a reasonable rate, which creates the question of how best to incorporate all the available drugs in an optimal manner. Additionally, there appears to be significant progress in reduced-intensity allogeneic stem cell transplants for low-grade lymphomas.
New and Novel Agents for the Treatment of Non-Hodgkin’s Lymphoma: A Report from the 2008 Meeting of the American Society of Hematology (1/26/2009)
The 2008 ASH meeting featured several reports of new agents that are showing promise in the treatment of Non-Hodgkin’s Lymphoma.
Survival Rates Improving in Childhood Hematologic Cancers (9/29/2008)
Five- and 10-year survival rates in childhood hematalogic cancers have significantly improved since 1990, according to the results of a study recently published in the Journal of the National Cancer Institute.
Non-Hodgkin's Lymphoma - RecurrentSurvivors of Some Childhood Cancers May Face Cognitive Impairment (5/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.
Children and Teens Have Better NHL Survival than Young Adults (3/15/2010)
Even after accounting for stage at diagnosis and subtype of non-Hodgkin’s lymphoma (NHL), children and teens with NHL have better survival than young adults with NHL. These results were published in the Archives of Pediatrics and Adolescent Medicine.
Veltuzumab Effective for Refractory Non-Hodgkin’s Lymphoma (7/28/2009)
Veltuzumab is safe and effective for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma, according to the results of a study published in the Journal of Clinical Oncology.
New and Novel Agents for the Treatment of Non-Hodgkin’s Lymphoma: A Report from the 2008 Meeting of the American Society of Hematology (1/26/2009)
The 2008 ASH meeting featured several reports of new agents that are showing promise in the treatment of Non-Hodgkin’s Lymphoma.
Treanda® Approved for Recurrent NHL (11/3/2008)
The United States Food and Drug Administration has approved Treanda® (bendamustine hydrochloride) for the treatment of slow-growing (indolent) B-cell non-Hodgkin's lymphoma (NHL) that has progressed either during therapy or within six months of therapy including Rituxan® (rituximab). Treanda is already approved for the treatment of chronic lymphocytic leukemia (CLL).
Non-Hodgkin's Lymphoma - T-CellIstodax Active against Refractory Cutaneous T-cell Lymphoma (8/31/2010)
Final results from a Phase II clinical trial provide additional evidence that Istodax® (romidepsin) is active against refractory cutaneous T-cell lymphoma. These results were published in the Journal of Clinical Oncology.
Survivors of Some Childhood Cancers May Face Cognitive Impairment (5/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.
Ontak Delays Progression of Patients with Cutaneous T-cell Lymphoma (3/29/2010)
Among patients with cutaneous T-cell lymphoma, treatment with the drug Ontak® (denileukin diftitox) slows disease progression. These results were reported in the Journal of Clinical Oncology.
Children and Teens Have Better NHL Survival than Young Adults (3/15/2010)
Even after accounting for stage at diagnosis and subtype of non-Hodgkin’s lymphoma (NHL), children and teens with NHL have better survival than young adults with NHL. These results were published in the Archives of Pediatrics and Adolescent Medicine.
Allogeneic Stem Cell Transplantation Effective for Angioimmunoblastic T-Cell Lymphoma (7/27/2009)
Among patients with a type of T-cell non-Hodgkin’s lymphoma known as angioimmunoblastic T-cell lymphoma (AITL), treatment with allogeneic stem cell transplantation results in long-term disease-free survival in approximately 50% of patients. The results of this study were published in the Journal of Clinical Oncology.
Non-Hodgkin's Lymphoma - Mantle CellSurvivors of Some Childhood Cancers May Face Cognitive Impairment (5/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.
Children and Teens Have Better NHL Survival than Young Adults (3/15/2010)
Even after accounting for stage at diagnosis and subtype of non-Hodgkin’s lymphoma (NHL), children and teens with NHL have better survival than young adults with NHL. These results were published in the Archives of Pediatrics and Adolescent Medicine.
The American Society of Clinical Oncology 2008: Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia (2/2/2009)
At the 2008 meeting of the American Society of Clinical Oncology (ASCO), there were more than 100 abstracts devoted to the treatment of lymphoma. There is increasing evidence that survival of patients with lymphoma and chronic lymphocytic leukemia (CLL) is steadily increasing. New drugs are being developed at a reasonable rate, which creates the question of how best to incorporate all the available drugs in an optimal manner. Additionally, there appears to be significant progress in reduced-intensity allogeneic stem cell transplants for low-grade lymphomas.
Intensive Chemotherapy Prolongs Remission of Mantle Cell Lymphoma (12/12/2008)
In a study of intensive chemotherapy for mantle cell lymphoma, more than half of patients 65 or younger were still in remission after seven years. These results were presented at the 50th Annual Meeting of the American Society of Hematology.
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma (4/1/2008)
Statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL), according to a recently published article in PLoS Med (the Public Library of Science journal).
|
|
